December 18, 2014 8:47 PM ET


Company Overview of Solasia Pharma K.K.

Company Overview

Solasia Pharma K.K. engages in developing, marketing, and importing/exporting oncology products. It focuses on developing and commercializing assets in the oncology/hematology fields. The company also provides SP-01 Sancuso, a transdermal system that delivers the anti-emetic and granisetron into the patient’s bloodstream who cannot swallow medicines due to nausea or mucositis; and SP-02 Darinaparsin, a mitochondrial-targeted agent (organic arsenic) for the treatment of various hematologic and solid cancers. It serves customers in Japan, China, Hong Kong, Macau, Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, the Philippines, Thailand, and internationally. Solasia Pharm...

3rd Floor

Shiodome Building

1-2-20, Kaigan


Tokyo,  105-0022


Founded in 2006


81 3 6721 8332


81 3 6721 2020

Key Executives for Solasia Pharma K.K.

President and Representative Director
Founder and Director
Acting Chief Financial Officer
Vice President of Corporate Development
Compensation as of Fiscal Year 2014.

Solasia Pharma K.K. Key Developments

Solasia Pharma KK Announces Management Changes; Receives Clinical Trial Permit from China SFDA for SP-01

Solasia Pharma KK announced a change in its executive leadership team. Yoshihiro Arai, currently General Manager and Head of Development of Solasia Pharma K.K., has been promoted to President and Representative Director of the company. Current Chief Executive Officer Steve Engen has announced his departure to pursue a new career opportunity. Mr. Arai joined Solasia Pharma K.K. in September 2007 with responsibility for all product development including clinical development and regulatory affairs. In order to progress clinical development in China, the company has established operations in Beijing and has hired core development and regulatory affairs staff. Furthermore, Ms. Vivian Zhang has joined the company as Solasia China General Manager and will be based in Shanghai. Vivian will build the Solasia China sales and marketing team, and prepare Sancuso(R) for China commercialization. Vivian joins Solasia after a career in marketing and sales at Shanghai Roche where she was responsible for Avastin(R) and Tarceva(R), two key oncology products for Roche in China. The company also announced receipt of the Clinical Trial Permit (CTP) from the China SFDA for SP-01 (brand name: Sancuso(R)), the company's product for the treatment of chemotherapy-induced nausea and vomiting. Having received the CTP, the company said it is now preparing to initiate the required pivotal studies, and expects to file a New Drug Application (NDA) in China in the fourth quarter of 2013.

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Solasia Pharma K.K., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at